If passed, TROA would: Permanently allow Medicare Part D to cover FDA-approved anti-obesity medications Expand Medicare Part B coverage of intensive behavioral therapy for obesity to include a wider range of providers (not just primary care physicians) However, in April 2025, CMS announced it would not include Medicare Part D coverage of obesity drugs in its rule changes for 2026, stating the proposal was "not appropriate at this time." That decision pushed the issue back to Congress, where the TROA remains under consideration
Committed to helping clients achieve wellness inside and out, Belle Medical has partnered with compounding pharmacies to create a unique blend of semaglutide plus vitamin B12 to increase the drugs efficacy while reducing common side effects
Obesity Reviews: An Official Journal of the International Association for the Study of Obesity, 19(1), 8197
The mechanism involves prolonged NSAID contact with stomach tissue due to semaglutide-induced gastric stasis
By binding to regional receptors in the gastrointestinal tract, GLP-1s alter gut motility in different areas of your intestines, affecting the physical contractions which push food (and waste) through your body
Key takeaways Some Aetna plans cover Wegovy, while others specifically do not cover weight loss medications
